Home » Stocks » Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. (ICPT)

Stock Price: $47.09 USD 0.57 (1.23%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.55B
Revenue (ttm) 272.40M
Net Income (ttm) -347.39M
Shares Out 32.94M
EPS (ttm) -10.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $47.09
Previous Close $46.52
Change ($) 0.57
Change (%) 1.23%
Day's Open 47.21
Day's Range 45.08 - 47.24
Day's Volume 1,126,683
52-Week Range 44.50 - 125.00

More Stats

Market Cap 1.55B
Enterprise Value 1.54B
Earnings Date (est) Jul 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.94M
Float 26.63M
EPS (basic) -10.74
EPS (diluted) -10.74
FCF / Share -7.76
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.80M
Short Ratio 7.12
Short % of Float 27.88%
Beta 1.81
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 5.69
PB Ratio 44.19
Revenue 272.40M
Operating Income -311.93M
Net Income -347.39M
Free Cash Flow -252.75M
Net Cash 15.08M
Net Cash / Share 0.46
Gross Margin 90.96%
Operating Margin -114.51%
Profit Margin -127.50%
FCF Margin -92.79%
ROA -35.43%
ROE -295.33%
ROIC -27.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (24)

Buy 7
Overweight 0
Hold 17
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$70.77*
(50.29% upside)
Low
46.0
Current: 47.09
High
180.0
Target: 70.77
*Average 12-month price target from 22 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue25218013124.952.781.741.622.451.81-
Revenue Growth40.15%37.3%424.85%796.87%59.7%7.4%-33.69%35.51%--
Gross Profit24817713024.952.781.741.622.451.81-
Operating Income-312-285-336-403-229-113-39.45-18.91-13.83-16.35
Net Income-345-309-360-413-226-283-67.79-43.64-12.74-15.09
Shares Outstanding31.6528.4625.0524.6623.6920.7818.036.283.333.33
Earnings Per Share-10.89-10.86-14.38-16.74-9.56-13.63-3.76-7.36-4.73-5.40
Operating Cash Flow-237-241-265-342-163-87.74-28.01-15.752.61-13.66
Capital Expenditures-1.14-0.17-10.39-5.08-5.94-4.64-1.63-0.04-0.06-0.03
Free Cash Flow-238-241-276-348-169-92.38-29.64-15.792.54-13.69
Cash & Equivalents65743641568962824014511017.7115.50
Total Debt532371356341----0.080.33
Net Cash / Debt12564.9159.2434862824014511017.6315.16
Assets75550948473965625415011219.4717.12
Liabilities70349046842453.6123.2667.9146.2722.038.80
Book Value51.5619.1316.3931560223182.4165.91-2.568.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intercept Pharmaceuticals, Inc.
Country United States
Employees 583
CEO Mark E. Pruzanski

Stock Information

Ticker Symbol ICPT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ICPT
IPO Date October 11, 2012

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.